Skip to main content
Open Access Publications from the University of California

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation

  • Author(s): Eric, L
  • Yeo, CJ
  • Lillemoe, KD
  • Biedrzycki, B
  • Kobrin, B
  • Herman, J
  • Sugar, E
  • Piantadosi, S
  • Cameron, JL
  • Solt, S
  • Onners, B
  • Tartakovsky, I
  • Choi, M
  • Sharma, R
  • Illei, PB
  • Ralph H., H
  • Abrams, RA
  • Le, D
  • Elizabeth, J
  • Laheru, D
  • et al.

Purpose: Surgical resection provides the only possibility of cure for pancreas cancer. A standard adjuvant approach has not been established. We tested the safety and efficacy of a granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy administered in patients with resected pancreatic adenocarcinoma. Patients andMethods: A single institution phase II study of 60 patients with resected pancreatic adenocarcinoma was performed. Each immunotherapy treatment consisted of a total of 5 × 108GM-CSF-secreting cells distributed equally among 3 lymph node regions. The first immunotherapy treatment was administered 8 to 10 weeks after surgical resection. Subsequently, patients received 5-FU based chemoradiation. Patientswho remained disease-free after completion of chemoradiotherapy received treatments 2 to 4, each 1 month apart. A fifth and final booster was administered 6 months after the fourth immunotherapy.The primary endpointwas disease free survival and secondary endpoints were overall survival and toxicity, and the induction of mesothelinspecific T cell responses. Results: Themedian disease-free survival is 17.3months (95% CI, 14.6-22.8) with median survival of 24.8 months (95% CI, 21.2-31.6). The administration of immunotherapy was well tolerated. In addition, the postimmunotherapy induction of mesothelin-specific CD8+ T cells in HLA-A1+ and HLA-A2+ patients correlates with disease-free survival. Conclusions: An immunotherapy approach integrated with chemoradiation is safe and demonstrates an overall survival that compares favorably with published data for resected pancreas cancer. These data suggest additional boost immunotherapies given at regular intervals beyond 1 year postsurgery should be tested in future studies, and provide the rationale for conducting a multicenter phase II study. Copyright © 2011 by Lippincott Williams & Wilkins.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item